<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980041</url>
  </required_header>
  <id_info>
    <org_study_id>IPI-549-02</org_study_id>
    <nct_id>NCT03980041</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination With IPI-549 Compared to Nivolumab Monotherapy in the Treatment of Patients With Immune Therapy-Naïve, Advanced Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Infinity Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Infinity Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the effect of IPI-549 in combination with nivolumab
      when compared to nivolumab monotherapy in advanced urothelial cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study IPI-549-02 is a multi-national, prospective, randomized, active-control Phase II trial
      to evaluate the efficacy and safety of IPI 549 administered in combination with nivolumab
      compared to nivolumab monotherapy.

      The study will enroll approximately 160 checkpoint-naïve, advanced urothelial cancer patients
      who have progressed or recurred following treatment with platinum-based chemotherapy.
      Patients will be randomized 2:1 to receive intravenous (IV) nivolumab 480 mg every 4 weeks
      (Q4W) in combination with oral (PO) IPI 549 40 mg once daily (QD) or IV nivolumab 480 mg Q4W
      in combination with placebo PO QD.

      Eligible patients who have confirmed progression of disease during treatment with nivolumab
      monotherapy may crossover to the combination treatment arm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2019</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) per RECISTv1.1</measure>
    <time_frame>First dosing date to date of confirmed disease progression, assessed up to 24 months</time_frame>
    <description>ORR is defined as best response of complete response (CR) or partial response (PR) as measured by RECIST v1.1.
RECIST 1.1 = Response Evaluation Criteria in Solid Tumors. CR= Disappearance of all extranodal target lesions. All pathological lymph nodes must have decreased to &lt;10 mm in short axis. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>First dosing date to date of first objective response, assessed up to 24 months</time_frame>
    <description>TTR is defined as the time from the first dose of study treatment to first objective response [complete response (CR) or partial response (PR)] in patients with CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Date of first objective response to date of confirmed disease progression, assessed up to 24 months</time_frame>
    <description>DOR is defined as the time from the first objective response (CR or PR) to documented disease progression in patients with CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>First dosing to date to confirmed disease progression or death, assessed up to 48 months</time_frame>
    <description>PFS is defined as the time from the first dose of study treatment to documented disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in thyroid stimulating hormone (TSH)</measure>
    <time_frame>Pre-treatment (within 7 days of first dose) to date of confirmed disease progression, assessed up to 24 months</time_frame>
    <description>If TSH result is abnormal, subsequent testing of Free T3 and free T4 required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in electrocardiograms (ECGs)</measure>
    <time_frame>Screening to date of confirmed disease progression, assessed up to 24 months</time_frame>
    <description>ECGs assess heart problems by measuring the electrical activity generated by the heart as it contracts. The components that will be assessed during the ECG are P wave, QRS complex, ST segment, and T wave.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Eastern Cooperative Oncology Group (ECOG) performance</measure>
    <time_frame>Screening to date of confirmed disease progression, assessed up to 24 months</time_frame>
    <description>ECOG performance status describes the level of impact that disease has on the patient's daily living abilities. Scale ranges from 0 (Fully active and able to carry on all pre-disease performance without restriction) to 5 (Dead).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population Pharmacokinetics (PK) of IPI-549-01</measure>
    <time_frame>Pre-dose, 0.5, 1.5, 3 and 6 hours following administration on Day 1 of Cycles 1 and 2 (each cycle is 28 days)</time_frame>
    <description>IPI-549 blood concentrations in ng/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of Nivolumab</measure>
    <time_frame>Pre-infusion and within 2 minutes of end of infusion on Day 1 of Cycles 1 and 4; Pre-infusion on Day 1 of Cycles 2 and 3, and every 4 cycles starting at Cycle 5 (each cycle is 28 days)</time_frame>
    <description>Nivolumab blood concentrations will be assayed in ug/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in pulse rate</measure>
    <time_frame>Screening to date of confirmed disease progression, assessed up to 24 months</time_frame>
    <description>Pulse rate as measured in beats per minute (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in temperature</measure>
    <time_frame>Screening to date of confirmed disease progression, assessed up to 24 months</time_frame>
    <description>Temperature as measured in celsius.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in respiration rate</measure>
    <time_frame>Screening to date of confirmed disease progression, assessed up to 24 months</time_frame>
    <description>Respiration rate as measured in breaths per minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in blood pressure</measure>
    <time_frame>Screening to date of confirmed disease progression, assessed up to 24 months</time_frame>
    <description>Systolic and diastolic blood pressure as measured in mmHg.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Solid Tumor</condition>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>IPI-549 + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive IPI-549 orally (PO) daily in combination with nivolumab IV infusion every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Nivolumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive placebo orally (PO) daily in combination with nivolumab IV infusion every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPI-549</intervention_name>
    <description>IPI-549 (40mg QD) administered orally in 28-day cycles</description>
    <arm_group_label>IPI-549 + Nivolumab</arm_group_label>
    <other_name>IPI549</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab (480mg Q4W) administered intravenously (IV) in 28-day cycles</description>
    <arm_group_label>IPI-549 + Nivolumab</arm_group_label>
    <arm_group_label>Placebo + Nivolumab</arm_group_label>
    <other_name>OPDIVO®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo administered orally in 28-day cycles</description>
    <arm_group_label>Placebo + Nivolumab</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed urothelial carcinoma of the renal pelvis,
             ureter, bladder, or urethra

          -  Measurable disease by CT or MRI as defined by RECIST v1.1

          -  Disease progression or recurrence after treatment:

          -  i) With at least 1 platinum-based chemotherapy regimen for the treatment of metastatic
             (Stage IV) or locally advanced unresectable disease; or

          -  ii) With disease recurrence within 1 year of completing a platinum-based neoadjuvant
             or adjuvant therapy

          -  Subject that have received more than 2 prior lines of chemotherapy must not have liver
             metastases

          -  Tumor tissues (archived or new biopsy) must be provided for biomarker analysis

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤1

          -  Blood sample must be provided for mMDSC levels for randomization into the study

        Exclusion Criteria:

          -  Active brain metastases or leptomeningeal metastases

          -  Any serious or uncontrolled medical disorder that may interfere with study
             treatment/interpretation

          -  Prior malignancy active within the previous 3 years except for local or organ confined
             early stage cancer that has been apparently cured

          -  Active, known, or suspected autoimmune disease

          -  A condition requiring systemic treatment with either corticosteroids (&gt;10 mg daily
             prednisone equivalents) or other immunosuppressive medications within 14 day of study
             drug administration

          -  Prior therapy with anti-tumor vaccines, any T cell co-stimulation or checkpoint
             pathways, or IPI-549

          -  Prior surgery or gastrointestinal dysfunction that may affect drug absorption

          -  Past medical history of interstitial lung disease

          -  History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia
             requiring medication or mechanical control

          -  Positive test for hepatitis B, C or HIV

          -  Dependent on continuous supplemental oxygen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Halle Zhang, PhD, RN</last_name>
    <role>Study Director</role>
    <affiliation>Infinity Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miriam Brody, MPH</last_name>
    <phone>617-453-1142</phone>
    <email>Miriam.Brody@infi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Roberts</last_name>
    <phone>617-453-1298</phone>
    <email>MARIO275@infi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Parkview Physicians</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhentao Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of MD - Greenebaum Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arif Hussain, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Heath, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coborn Cancer Center</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Jurgens, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Gartrell, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bon Secours St. Francis Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Dyar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith McKean, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologicka Klinika</name>
      <address>
        <city>Praha</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Buchler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélien Carnot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwenaëlle Gravis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine Borchiellini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Barthelemy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien Pouessel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto per la Ricerca e la Cura del Cancro (IRCC)</name>
      <address>
        <city>Candiolo</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Aglietta, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <zip>47104</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ugo De Giorgi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Tambaro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dzienny Oddzial Chemioterapii</name>
      <address>
        <city>Racibórz</city>
        <zip>47-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanslik Jerzy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>EXAMEN sp</name>
      <address>
        <city>Skorzewo</city>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Tomczak, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oddzial Chorob Rozrostowych Wojewodzki Szpital</name>
      <address>
        <city>Łódź</city>
        <zip>93-153</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Ulanska, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksandar Janicic, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute for Oncology of Vojvodina</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21 204</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lazar Popovic, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Institute Catalan of Oncology</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Garcia del Muro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>8005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Pablo Maroto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IMQ Zorrotzaurre</name>
      <address>
        <city>Bilbao</city>
        <zip>48180</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Fernandez Rodriguez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Grande, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Gajate, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitatio HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Sevillano Fernandez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Solis Hernandez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Begoña Perez Valderrama, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.infi.com/home/our-development-program/ipi-549/</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

